Frequently asked questions
Your questions, answered
The platforms, the services, licensing, manufacturing, and working with us. If you don’t see your question, ask us and we’ll answer it.
Frequently asked questions
The platforms, the services, licensing, manufacturing, and working with us. If you don’t see your question, ask us and we’ll answer it.
B-Body is a bispecific platform: two binding arms on one IgG-like antibody. T-Body is a trispecific: three arms for three targets. They share the same constant-domain engineering, but T-Body extends the B-Body architecture to a third Fab arm.
The engineering sits in the constant domains, not the variable ones. One Fab arm on a B-Body, or two on a T-Body, swaps its CH1/CL for proprietary CH3 domain pairs, so the correct heavy and light chains pair on their own. You don’t touch the binding regions, and there’s no common light chain to engineer.
No. Each arm keeps its own light chain. You bring the best binders for your target instead of forcing them onto a shared light chain.
Yes, both, across the Fab arms. The T-Body 24-construct matrix included three kappa and one lambda antibody.
Variable domains from any source: antibodies we discover or sequences you supply. The platforms were validated on clinical antibodies chosen for difficult developability, not cherry-picked easy ones.
1×1, 2×1, and 2×2 bispecifics on the B-Body scaffold. For three targets, T-Body puts three Fab arms on the same architecture.
IgG-like. Three Fab arms sit on a single antibody with an Fc, not a fusion of fragments, so it keeps a real antibody’s half-life and manufacturability.
Yes. Both platforms support payload conjugation, and Invenra has shown bispecific and trispecific ADCs that kill tumor cells across HER2-high, HER2-low, triple-negative breast cancer lines and more.
Yes. Two molecules are in the clinic, with several more expected this year.
Discovery is a full program: we source or screen binders, run them through matrix expression and characterization, and hand back a small set of fully characterized lead candidates. Express focuses on taking variable domains you already have and assembling, expressing, purifying, and characterizing them in the platform format.
A molecule and a complete data package, ready for cell line development: a development candidate in its final format, not just a sequence. You skip format engineering and move toward manufacturing. You also get a research use license as part of the program and an option to acquire a clinical/commercial license.
Yes. We share the full data set.
Yes. You own every lead we deliver.
You do, with us. It’s not a black box. We share all the data and work with you to select the best leads.
You help plan the project up front, we hold regular progress meetings, and you select the best lead candidate at the end.
You don’t have to decide up front. The bispecific data we collect during screening can inform a future trispecific program. Let the data decide.
It depends on the complexity of the project — anywhere from a few weeks to several months.
Since we work in close collaboration throughout the project, we are able to engineer your antibody to address challenging biology. We have an excellent track record at achieving our clients’ goals.
The B-Body antibodies have been proven to perform similarly to human IgG1 antibodies. To date, T-Body antibodies have demonstrated similar results.
No. The molecules are human IgGs, so they run on conventional Protein A, ion exchange, and standard polishing. An anti-CH1 affinity step is available for single-pass purity but isn’t required downstream.
Protein A or a single-step anti-CH1 capture, then ion exchange polishing. Low aggregate formation is confirmed by SEC and CE-SDS.
High! B-Body bispecifics reach 6–11 g/L, with over 99% of a 15×15 clinical matrix passing purity and yield (in at least one orientation). T-Body trispecifics ran up to 1.5 g/L transient and typically greater than 95% purity.
No. A monoclonal from our discovery service is unencumbered. You own the sequences, with no license to sign and no royalties or milestones.
Through a clear menu: a research-use license included with every project, an Early Decision license (a one-year option within six months of signing that locks in lower pricing), and a Standard license any time up to IND. All B-Body licensing runs through our partner Twist Bioscience.
A one-year licensing option you can take within six months of signing your project contract. It locks in lower pricing, and you don’t have to pick your lead until you exercise it.
Yes. An annual research-use (RUO) site license shares the full B-Body discovery platform IP with hands-on tech transfer, so your team generates leads in your own facility, with a clear path to clinical licensing later.
T-Body is a premium platform, and no two trispecific programs are the same. Engagements are custom, with co-discovery options, back-loaded payments, performance-based milestones, tiered royalties, and sublicensing all on the table.
Your variable domains stay yours. The platform technology is what’s licensed.
Not on B-Body — none of the three B-Body license types carry milestones or royalties. T-Body deals are custom and can include performance-based milestones and tiered royalties.
Mostly academia, startups, biotechs and pharma. The licensing is structured so any kind of organization can build on the platforms.
Tell us about your targets and what success looks like, and we’ll map out a path. Get in touch, and we’ll take it from there.
If it’s not here, the fastest way to an answer is to ask. Tell us about your program and we’ll get you the details.
Your information is 100% confidential.
We don't share your data with third parties, add you to marketing lists without permission, or contact you about anything other than this request. Target biology is treated as confidential. Need an NDA first? Just say so. We'll send one over.